Treatment of Helicobacter pylori infection: Current status and future concepts

Table 3 Use of different high dose dual therapies for Helicobacter pylori infection

Author	Role	Regiment	Patients, n	Eradication rate
				ITT	PP	CYP2C19
						EM	IM	PM
Bayerdörffer et al[99]	1st	OME 40 mg and AMO 750 mg tid for 14 d	139	89.0%	90.6%
Miehlke et al[110]	2nd	OME 40 mg and AMO 750 mg qid for 14 d	41	75.6%	83.8%
Furuta et al[100]	2nd	RAB 10 mg and AMO 500 mg qid for 14 d	12		100.0%	100.0%	100%
Furuta et al[111]	2nd	LAN 30 mg and AMO 500 mg qid for 14 d	32		96.9%	95.7%	100%	100%
Shirai et al[112]	2nd	RAB 10 mg and AMO 500 mg qid	66	90.9%	93.8%
Graham et al[113]	1st	ESO 40 mg and AMO 750 mg tid for 7 d	36	72.2%	74.2%
Kim et al[114]	1st	LAN 30 mg and AMO 750 mg tid for 14 d	104	67.3%	78.4%
Goh et al[115]	2nd	RAB 20 mg and AMO 1 g tid for 14 d	149	71.8%	75.4%

ITT: Intention-to-treat; PP: Per-protocol; OME: Omeprazole; AMO: Amoxicillin; RAB: Rabeprazole; LAN: Lansoprazole; ESO: Esomeprazole; tid: Three times daily; qid: Four times daily; 1^st: First-line treatment; 2^nd: Rescue treatment; EM: Extensive metabolizer; IM: Intermediate metabolizer.